Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Safety Study of Solriamfetol to Promote Wakefulness and Improve Cognition and Quality of Life in Patients With Primary Gliomas

NCT03868943 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT03868943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03868943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Safety Study of Solriamfetol to Promote Wakefulness and Improve Cognition and Quality of Life in Patients With Primary Gliomas
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 2
Overall status
Terminated
Start date
January 27, 2021
Completion date
November 22, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioma